Novartis Readies Sales Force For Galvus Ramp-Up In China; Abbott Improves Margin For Nutritionals – Emerging Market Earnings Roundup (Part 1)
By
Brian Yang / Email the Author / PharmAsia News Feb. 1, 2012 5:11 PM GMT
Features / Word Count: 1308 / Article # 28120201009
Executive Summary
Novartis calls 2012 its most challenging year. Abbott projects foreign exchange swings to lead to overall flat revenue growth. Yet both companies plan to offset losses through growth in emerging markets.
$85.00
Buy Now
For $85.00, purchase this 1308-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.